RU2017108634A - Отличные от человека животные, экспрессирующие антитела с общей легкой цепью - Google Patents

Отличные от человека животные, экспрессирующие антитела с общей легкой цепью Download PDF

Info

Publication number
RU2017108634A
RU2017108634A RU2017108634A RU2017108634A RU2017108634A RU 2017108634 A RU2017108634 A RU 2017108634A RU 2017108634 A RU2017108634 A RU 2017108634A RU 2017108634 A RU2017108634 A RU 2017108634A RU 2017108634 A RU2017108634 A RU 2017108634A
Authority
RU
Russia
Prior art keywords
mouse
human
light chain
sequence
rearranged
Prior art date
Application number
RU2017108634A
Other languages
English (en)
Russian (ru)
Inventor
Джон МКУИРТЕР
Лин МАКДОНАЛД
Шон СТИВЕНС
Сэмюэл ДЭВИС
Дэвид Р. БАКЛЕР
Каролина А. ХОСИЯВА
Эндрю Джей МЕРФИ
Original Assignee
Регенерон Фармасьютикалс, Инк.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=46000410&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=RU2017108634(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Регенерон Фармасьютикалс, Инк. filed Critical Регенерон Фармасьютикалс, Инк.
Publication of RU2017108634A publication Critical patent/RU2017108634A/ru

Links

Classifications

    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K67/00—Rearing or breeding animals, not otherwise provided for; New or modified breeds of animals
    • A01K67/027—New or modified breeds of vertebrates
    • A01K67/0275—Genetically modified vertebrates, e.g. transgenic
    • A01K67/0278—Knock-in vertebrates, e.g. humanised vertebrates
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K67/00—Rearing or breeding animals, not otherwise provided for; New or modified breeds of animals
    • A01K67/027—New or modified breeds of vertebrates
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/46—Hybrid immunoglobulins
    • C07K16/468—Immunoglobulins having two or more different antigen binding sites, e.g. multifunctional antibodies
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/8509—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells for producing genetically modified animals, e.g. transgenic
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/10—Cells modified by introduction of foreign genetic material
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2207/00—Modified animals
    • A01K2207/15—Humanized animals
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2217/00—Genetically modified animals
    • A01K2217/07—Animals genetically altered by homologous recombination
    • A01K2217/072—Animals genetically altered by homologous recombination maintaining or altering function, i.e. knock in
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2217/00—Genetically modified animals
    • A01K2217/15—Animals comprising multiple alterations of the genome, by transgenesis or homologous recombination, e.g. obtained by cross-breeding
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2227/00—Animals characterised by species
    • A01K2227/10—Mammal
    • A01K2227/105—Murine
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2267/00—Animals characterised by purpose
    • A01K2267/01—Animal expressing industrially exogenous proteins
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/515—Complete light chain, i.e. VL + CL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2800/00—Nucleic acids vectors
    • C12N2800/20—Pseudochromosomes, minichrosomosomes
    • C12N2800/204—Pseudochromosomes, minichrosomosomes of bacterial origin, e.g. BAC

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Zoology (AREA)
  • Biotechnology (AREA)
  • Biomedical Technology (AREA)
  • General Health & Medical Sciences (AREA)
  • Wood Science & Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Environmental Sciences (AREA)
  • Immunology (AREA)
  • Microbiology (AREA)
  • Veterinary Medicine (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Animal Husbandry (AREA)
  • Biodiversity & Conservation Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Cell Biology (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
RU2017108634A 2011-04-25 2012-04-24 Отличные от человека животные, экспрессирующие антитела с общей легкой цепью RU2017108634A (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US13/093,156 2011-04-25
US13/093,156 US20120021409A1 (en) 2010-02-08 2011-04-25 Common Light Chain Mouse

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
RU2013152221A Division RU2614859C2 (ru) 2011-04-25 2012-04-24 Отличные от человека животные, экспрессирующие антитела с общей легкой цепью

Publications (1)

Publication Number Publication Date
RU2017108634A true RU2017108634A (ru) 2019-01-22

Family

ID=46000410

Family Applications (2)

Application Number Title Priority Date Filing Date
RU2017108634A RU2017108634A (ru) 2011-04-25 2012-04-24 Отличные от человека животные, экспрессирующие антитела с общей легкой цепью
RU2013152221A RU2614859C2 (ru) 2011-04-25 2012-04-24 Отличные от человека животные, экспрессирующие антитела с общей легкой цепью

Family Applications After (1)

Application Number Title Priority Date Filing Date
RU2013152221A RU2614859C2 (ru) 2011-04-25 2012-04-24 Отличные от человека животные, экспрессирующие антитела с общей легкой цепью

Country Status (24)

Country Link
US (2) US20120021409A1 (OSRAM)
EP (2) EP2989893B1 (OSRAM)
JP (2) JP6393613B2 (OSRAM)
KR (1) KR101995753B1 (OSRAM)
CN (2) CN103596424B (OSRAM)
AU (3) AU2012249953B2 (OSRAM)
BR (1) BR112013027420A2 (OSRAM)
CA (1) CA2846806A1 (OSRAM)
CY (2) CY1117606T1 (OSRAM)
DK (2) DK2989893T3 (OSRAM)
ES (2) ES2573828T5 (OSRAM)
HR (2) HRP20160484T4 (OSRAM)
HU (2) HUE027949T2 (OSRAM)
IL (1) IL228929A0 (OSRAM)
LT (1) LT2989893T (OSRAM)
MX (1) MX353609B (OSRAM)
PL (2) PL2701499T5 (OSRAM)
PT (1) PT2989893T (OSRAM)
RS (2) RS59331B1 (OSRAM)
RU (2) RU2017108634A (OSRAM)
SG (1) SG194466A1 (OSRAM)
SI (2) SI2989893T1 (OSRAM)
SM (2) SMT201900514T1 (OSRAM)
WO (1) WO2012148873A2 (OSRAM)

Families Citing this family (94)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6596541B2 (en) * 2000-10-31 2003-07-22 Regeneron Pharmaceuticals, Inc. Methods of modifying eukaryotic cells
SI1523496T1 (sl) 2002-07-18 2011-11-30 Merus B V Rekombinantno proizvajanje zmesi protiteles
USRE47770E1 (en) 2002-07-18 2019-12-17 Merus N.V. Recombinant production of mixtures of antibodies
US20100069614A1 (en) 2008-06-27 2010-03-18 Merus B.V. Antibody producing non-human mammals
EP2395017A3 (en) 2003-05-30 2012-12-19 Merus B.V. Design and use of paired variable regions of specific binding molecules
EP2006381B1 (en) 2006-03-31 2016-02-03 Chugai Seiyaku Kabushiki Kaisha Method for controlling blood pharmacokinetics of antibodies
CA2700701C (en) 2007-09-26 2020-12-29 Chugai Seiyaku Kabushiki Kaisha Method of modifying isoelectric point of antibody via amino acid substitution in cdr
US9676845B2 (en) 2009-06-16 2017-06-13 Hoffmann-La Roche, Inc. Bispecific antigen binding proteins
PT2564695E (pt) 2009-07-08 2015-06-03 Kymab Ltd Modelos animais e moléculas terapêuticas
US9445581B2 (en) 2012-03-28 2016-09-20 Kymab Limited Animal models and therapeutic molecules
US9796788B2 (en) 2010-02-08 2017-10-24 Regeneron Pharmaceuticals, Inc. Mice expressing a limited immunoglobulin light chain repertoire
DK2505654T4 (da) 2010-02-08 2020-07-27 Regeneron Pharma Mus med fælles letkæde
US20130045492A1 (en) 2010-02-08 2013-02-21 Regeneron Pharmaceuticals, Inc. Methods For Making Fully Human Bispecific Antibodies Using A Common Light Chain
CA3250882A1 (en) 2010-08-02 2025-11-29 Regeneron Pharamaceuticals, Inc. Mice that Make Binding Proteins Comprising VL Domains
MX349057B (es) 2010-11-30 2017-07-07 Chugai Pharmaceutical Co Ltd Agente terapeutico que induce citotoxicidad.
SI2738258T2 (sl) 2011-02-25 2023-05-31 Regeneron Pharmaceuticals, Inc. Miši ADAM6
BR112013019975A2 (pt) 2011-02-28 2017-08-01 Hoffmann La Roche proteínas de ligação de antígeno, composição farmacêutica, uso de uma proteína de ligação de antígeno, método para o tratamento de um paciente e método para a preparação de uma proteína de ligação de antígeno, ácido nucleico, vetor e célula hospedeira"
CA2824824A1 (en) 2011-02-28 2012-09-07 F. Hoffmann-La Roche Ag Monovalent antigen binding proteins
MY172718A (en) 2011-08-05 2019-12-11 Regeneron Pharma Humanized universal light chain mice
WO2013041844A2 (en) 2011-09-19 2013-03-28 Kymab Limited Antibodies, variable domains & chains tailored for human use
CA2791109C (en) 2011-09-26 2021-02-16 Merus B.V. Generation of binding molecules
WO2013045916A1 (en) 2011-09-26 2013-04-04 Kymab Limited Chimaeric surrogate light chains (slc) comprising human vpreb
MY172946A (en) 2011-10-17 2019-12-16 Regeneron Pharma Restricted immunoglobulin heavy chain mice
US9253965B2 (en) 2012-03-28 2016-02-09 Kymab Limited Animal models and therapeutic molecules
KR102081657B1 (ko) 2011-12-20 2020-02-26 리제너론 파마슈티칼스 인코포레이티드 인간화 경쇄 마우스
ES2665793T3 (es) 2012-03-16 2018-04-27 Regeneron Pharmaceuticals, Inc. Anticuerpos de cadena ligera modificada mediante ingeniería genética con histidina y roedores modificados genéticamente para la generación de los mismos
CN104302170B (zh) 2012-03-16 2016-09-28 瑞泽恩制药公司 生产具有ph依赖性结合特性的抗原结合蛋白的小鼠
NZ730271A (en) 2012-03-16 2022-09-30 Regeneron Pharma Non-human animals expressing ph-sensitive immunoglobulin sequences
US20140013456A1 (en) 2012-03-16 2014-01-09 Regeneron Pharmaceuticals, Inc. Histidine Engineered Light Chain Antibodies and Genetically Modified Non-Human Animals for Generating the Same
GB2502127A (en) 2012-05-17 2013-11-20 Kymab Ltd Multivalent antibodies and in vivo methods for their production
US10251377B2 (en) 2012-03-28 2019-04-09 Kymab Limited Transgenic non-human vertebrate for the expression of class-switched, fully human, antibodies
CA2870821C (en) 2012-04-20 2022-06-14 Merus B.V. Methods and means for the production of ig-like molecules
HUE055617T2 (hu) * 2012-06-12 2021-12-28 Regeneron Pharma Korlátozott immunglobulin nehézlánc lókuszokkal rendelkezõ, humanizált, nem humán élõlények
US20150203591A1 (en) 2012-08-02 2015-07-23 Regeneron Pharmaceuticals, Inc. Mutivalent antigen-binding proteins
ES2678221T3 (es) 2013-02-20 2018-08-09 Regeneron Pharmaceuticals, Inc. Animales no humanos con secuencias de cadena pesada de inmunoglobulina modificadas
LT3501272T (lt) * 2013-03-13 2023-03-27 Regeneron Pharmaceuticals, Inc. Pelės, vykdančios imunoglobulino lengvosios grandinės riboto rinkinio raišką
EP2970437A1 (en) * 2013-03-13 2016-01-20 Regeneron Pharmaceuticals, Inc. Common light chain mouse
US9788534B2 (en) 2013-03-18 2017-10-17 Kymab Limited Animal models and therapeutic molecules
KR102049990B1 (ko) 2013-03-28 2019-12-03 삼성전자주식회사 c-Met 항체 및 VEGF 결합 단편이 연결된 융합 단백질
US9783618B2 (en) 2013-05-01 2017-10-10 Kymab Limited Manipulation of immunoglobulin gene diversity and multi-antibody therapeutics
US11707056B2 (en) 2013-05-02 2023-07-25 Kymab Limited Animals, repertoires and methods
US9783593B2 (en) 2013-05-02 2017-10-10 Kymab Limited Antibodies, variable domains and chains tailored for human use
SG10201810825YA (en) * 2013-09-18 2019-01-30 Regeneron Pharma Histidine engineered light chain antibodies and genetically modified non-human animals for generating the same
NL2013554B1 (en) 2013-10-01 2016-01-08 Kymab Ltd Animal models and therapeutic molecules.
RU2016115866A (ru) 2013-10-11 2017-11-16 Ф. Хоффманн-Ля Рош Аг Мультиспецифические антитела с обменянными доменами и одинаковыми вариабельными доменами легкой цепи
BR112016021572A2 (pt) * 2014-03-21 2017-10-03 Regeneron Pharma Métodos para preparar um animal não humano geneticamente modificado e para produzir proteínas de ligação, hibridoma, ácido nucleico, célula, e, proteína de ligação
BR112016021679A2 (pt) 2014-03-21 2018-12-04 Regeneron Pharmaceuticals, Inc. proteína de ligação ao antígeno, métodos de produção de uma proteína de ligação ao antígeno e de identificação de uma ou mais proteínas de ligação ao antígeno, hibridoma, ácido nucleico, célula, e, animal não humano geneticamente modificado.
PL3151921T3 (pl) 2014-06-06 2020-02-28 Bristol-Myers Squibb Company Przeciwciała przeciwko receptorowi indukowanego glukokortykoidami czynnika martwicy nowotworu (gitr) i ich zastosowania
MA40764A (fr) * 2014-09-26 2017-08-01 Chugai Pharmaceutical Co Ltd Agent thérapeutique induisant une cytotoxicité
CN106999566B (zh) 2014-10-03 2022-01-28 麻省理工学院 结合埃博拉病毒糖蛋白的抗体及其用途
LT3221363T (lt) 2014-11-21 2020-08-10 Bristol-Myers Squibb Company Antikūnai prieš cd73 ir jų panaudojimas
PT3233912T (pt) 2014-12-19 2021-08-09 Regenesance B V Antocorpos que se ligam a c6 humano e utilizações destes
SG10202006538TA (en) 2014-12-23 2020-08-28 Bristol Myers Squibb Co Antibodies to tigit
CA2979702A1 (en) * 2015-03-19 2016-09-22 Regeneron Pharmaceuticals, Inc. Non-human animals that select for light chain variable regions that bind antigen
WO2016159213A1 (ja) 2015-04-01 2016-10-06 中外製薬株式会社 ポリペプチド異種多量体の製造方法
JP6797137B2 (ja) 2015-05-29 2020-12-09 ブリストル−マイヤーズ スクイブ カンパニーＢｒｉｓｔｏｌ−Ｍｙｅｒｓ Ｓｑｕｉｂｂ Ｃｏｍｐａｎｙ Ｏｘ４０に対する抗体およびその使用
EP3313886A1 (en) 2015-06-29 2018-05-02 The Rockefeller University Antibodies to cd40 with enhanced agonist activity
TW201713690A (zh) * 2015-08-07 2017-04-16 再生元醫藥公司 抗ａｎｇｐｔｌ８抗體及其用途
CN108024523A (zh) * 2015-08-27 2018-05-11 晶体生物科学股份有限公司 用于产生具有共同轻链的抗体的转基因动物
TWI752920B (zh) 2015-10-12 2022-01-21 美商再生元醫藥公司 活化瘦素受體的抗原結合蛋白
ES2926969T3 (es) 2015-11-19 2022-10-31 Bristol Myers Squibb Co Anticuerpos contra el receptor de factor de necrosis de tumor inducido por glucocorticoides (gitr) y usos de los mismos
SG10201914034WA (en) 2016-01-13 2020-03-30 Regeneron Pharma Rodents having an engineered heavy chain diversity region
KR20230038311A (ko) 2016-03-04 2023-03-17 브리스톨-마이어스 스큅 컴퍼니 항-cd73 항체와의 조합 요법
CA3016534A1 (en) 2016-03-04 2017-09-08 The Rockefeller University Antibodies to cd40 with enhanced agonist activity
WO2017159287A1 (ja) 2016-03-14 2017-09-21 中外製薬株式会社 癌の治療に用いるための細胞傷害誘導治療剤
EA039084B1 (ru) 2016-05-09 2021-12-01 Бристол-Майерс Сквибб Компани Антитела к tl1a и их применения
JP7324583B2 (ja) 2016-05-20 2023-08-10 リジェネロン・ファーマシューティカルズ・インコーポレイテッド 複数のガイドｒｎａを使用して免疫寛容を破綻させるための方法
PT3462853T (pt) 2016-06-03 2023-04-21 Regeneron Pharma Animais não humanos que expressam desoxinucleotidiltransferase terminal exógena
US20190248893A1 (en) 2016-07-14 2019-08-15 Bristol-Myers Squibb Company Antibodies against tim3 and uses thereof
US10981976B2 (en) 2016-08-31 2021-04-20 University Of Rochester Human monoclonal antibodies to human endogenous retrovirus K envelope (HERV-K) and use thereof
US11267873B2 (en) 2016-10-13 2022-03-08 Massachusetts Institute Of Technology Antibodies that bind zika virus envelope protein and uses thereof
US11142570B2 (en) 2017-02-17 2021-10-12 Bristol-Myers Squibb Company Antibodies to alpha-synuclein and uses thereof
TWI788340B (zh) 2017-04-07 2023-01-01 美商必治妥美雅史谷比公司 抗icos促效劑抗體及其用途
GB201710984D0 (en) * 2017-07-07 2017-08-23 Kymab Ltd Cells, vertebrates, populations & methods
WO2019126194A1 (en) 2017-12-18 2019-06-27 Regeneron Pharmaceuticals, Inc. Angptl8 assay and uses thereof
CN120192415A (zh) 2018-01-12 2025-06-24 百时美施贵宝公司 抗tim3抗体及其用途
KR102761890B1 (ko) 2018-03-23 2025-02-06 브리스톨-마이어스 스큅 컴퍼니 Mica 및/또는 micb에 대한 항체 및 그의 용도
LT3772927T (lt) 2018-03-24 2025-02-10 Regeneron Pharmaceuticals, Inc. Genetiškai modifikuotos pelės arba žiurkės, skirtos gaminti terapinius antikūnus prieš peptidų- mhc kompleksus, jų gamybos būdai ir panaudojimas
HRP20250986T1 (hr) 2018-04-06 2025-10-24 Regeneron Pharmaceuticals, Inc. Antitijelo agonista leptinskog receptora za upotrebu u povećanju koštane mase kod osobe koja pati od metaboličke disfunkcije ili hipoleptinemije
IL318469A (en) 2018-06-14 2025-03-01 Regeneron Pharma Non-human animals capable of reorganizing transgenic DH-DH, and their uses
MY205758A (en) 2018-11-16 2024-11-12 Bristol Myers Squibb Co Anti-nkg2a antibodies and uses thereof
KR102570405B1 (ko) 2019-01-22 2023-08-25 브리스톨-마이어스 스큅 컴퍼니 Il-7r 알파 서브유닛에 대한 항체 및 이의 용도
CA3127153A1 (en) 2019-02-22 2020-08-27 Regeneron Pharmaceuticals, Inc. Rodents having genetically modified sodium channels and methods of use thereof
CN114585651A (zh) 2019-08-08 2022-06-03 再生元制药公司 新型抗原结合分子形式
KR20220110233A (ko) 2019-12-02 2022-08-05 리제너론 파마슈티칼스 인코포레이티드 펩티드-mhc ii 단백질 작제물 및 그의 용도
KR20210095781A (ko) 2020-01-24 2021-08-03 주식회사 에이프릴바이오 항원결합 단편 및 생리활성 이펙터 모이어티로 구성된 융합 컨스트럭트를 포함하는 다중결합항체 및 이를 포함하는 약학조성물
WO2021231732A1 (en) 2020-05-15 2021-11-18 Bristol-Myers Squibb Company Antibodies to garp
IL301137A (en) 2020-09-11 2023-05-01 Regeneron Pharma Identification and production of antigen-specific antibodies
WO2022132943A1 (en) 2020-12-16 2022-06-23 Regeneron Pharmaceuticals, Inc. Mice expressing humanized fc alpha receptors
CA3165366A1 (en) 2020-12-23 2022-06-30 Regeneron Pharmaceuticals, Inc. Nucleic acids encoding anchor modified antibodies and uses thereof
IL303865A (en) 2020-12-23 2023-08-01 Regeneron Pharma Methods for obtaining antibodies that bind transmembrane proteins and cells that produce them
TW202430641A (zh) * 2023-01-18 2024-08-01 美商基利科學股份有限公司 人類免疫球蛋白二元輕鏈轉殖基因構築體及其用途
EP4658687A1 (en) 2023-01-31 2025-12-10 University of Rochester Immune checkpoint blockade therapy for treating staphylococcus aureus infections
WO2025184208A1 (en) 2024-02-27 2025-09-04 Bristol-Myers Squibb Company Anti-ceacam5 antibodies and uses thereof

Family Cites Families (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1991000906A1 (en) 1989-07-12 1991-01-24 Genetics Institute, Inc. Chimeric and transgenic animals capable of producing human antibodies
ATE356869T1 (de) 1990-01-12 2007-04-15 Amgen Fremont Inc Bildung von xenogenen antikörpern
US5770429A (en) * 1990-08-29 1998-06-23 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
CA2089661C (en) 1990-08-29 2007-04-03 Nils Lonberg Transgenic non-human animals capable of producing heterologous antibodies
US7041871B1 (en) * 1995-10-10 2006-05-09 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
IL109168A0 (en) * 1993-04-01 1994-06-24 Univ Columbia A retroviral vector capable of transducing the aldehyde dehydrogenase-1 gene and making cells resistant to the chemotherapeutic agent cyclophosphamide and its derivatives and analogs
SI0970126T1 (en) * 1997-04-14 2001-08-31 Micromet Ag Novel method for the production of antihuman antigen receptors and uses thereof
AU751659B2 (en) 1997-05-02 2002-08-22 Genentech Inc. A method for making multispecific antibodies having heteromultimeric and common components
US6774279B2 (en) 1997-05-30 2004-08-10 Carnegie Institution Of Washington Use of FLP recombinase in mice
US6586251B2 (en) 2000-10-31 2003-07-01 Regeneron Pharmaceuticals, Inc. Methods of modifying eukaryotic cells
US6596541B2 (en) * 2000-10-31 2003-07-22 Regeneron Pharmaceuticals, Inc. Methods of modifying eukaryotic cells
MXPA05000511A (es) * 2001-07-12 2005-09-30 Jefferson Foote Anticuepros super humanizados.
ATE476503T1 (de) * 2001-10-01 2010-08-15 Deutsches Krebsforsch Verfahren zur herstellung von protein- bibliotheken und zur selektion von proteinen daraus
EP2319301B1 (en) * 2001-11-30 2017-09-06 Amgen Fremont Inc. Transgenic animals bearing human Ig lambda light chain genes
AU2003214842A1 (en) * 2002-01-17 2003-09-02 Albert Einstein College Of Medicine Of Yeshiva University Mutations caused by activation-induced cytidine deaminase
MXPA04012656A (es) * 2002-06-14 2005-08-15 Immunomedics Inc Anticuerpo hpam4 monoclonal humanizado.
SI1523496T1 (sl) * 2002-07-18 2011-11-30 Merus B V Rekombinantno proizvajanje zmesi protiteles
US20100069614A1 (en) * 2008-06-27 2010-03-18 Merus B.V. Antibody producing non-human mammals
EP2395017A3 (en) 2003-05-30 2012-12-19 Merus B.V. Design and use of paired variable regions of specific binding molecules
CN1560081A (zh) * 2004-02-17 2005-01-05 大连帝恩生物工程有限公司 用能产生人IgGl重链－κ轻链小鼠作为制备人源化单克隆抗体和应用
PT2767161T (pt) 2004-10-19 2018-04-20 Regeneron Pharma Método para gerar um animal homozigótico para uma modificação genética
AU2006322445B2 (en) * 2005-12-05 2011-05-12 Symphogen A/S Anti-orthopoxvirus recombinant polyclonal antibody
NZ573557A (en) 2006-06-02 2010-08-27 Regeneron Pharma High affinity antibodies to human il-6 receptor
US7608693B2 (en) * 2006-10-02 2009-10-27 Regeneron Pharmaceuticals, Inc. High affinity human antibodies to human IL-4 receptor
EP2134852A4 (en) * 2007-03-13 2010-04-28 Nat Jewish Health PROCESS FOR THE PRODUCTION OF ANTIBODIES
ITMI20071522A1 (it) * 2007-07-27 2009-01-28 Areta Internat S R L Vaccino idiotipico
EP2556747B1 (en) * 2008-06-27 2020-12-02 Merus N.V. Antibody producing transgenic mice
DK2356270T3 (da) * 2008-11-07 2016-12-12 Fabrus Llc Kombinatoriske antistofbiblioteker og anvendelser deraf
AU2010252939B2 (en) * 2009-05-29 2014-06-26 Morphosys Ag A collection and methods for its use
SI2975051T1 (sl) * 2009-06-26 2021-08-31 Regeneron Pharmaceuticals, Inc. Zlahka izolirana bispecifična protitelesa z nativnim imunoglobulinskim formatom
DK2505654T4 (da) * 2010-02-08 2020-07-27 Regeneron Pharma Mus med fælles letkæde
SG11201407644UA (en) 2012-06-05 2014-12-30 Regeneron Pharma Methods for making fully human bispecific antibodies using a common light chain

Also Published As

Publication number Publication date
SI2701499T2 (sl) 2022-01-31
WO2012148873A3 (en) 2013-02-07
AU2016202609A1 (en) 2016-05-19
EP2701499B2 (en) 2021-08-18
ES2573828T3 (es) 2016-06-10
MX353609B (es) 2018-01-18
SMT201900514T1 (it) 2019-11-13
EP2701499B9 (en) 2016-05-18
CY1122036T1 (el) 2020-10-14
ES2743681T3 (es) 2020-02-20
US20120021409A1 (en) 2012-01-26
DK2989893T3 (da) 2019-09-09
PT2989893T (pt) 2019-09-23
PL2701499T3 (pl) 2017-03-31
KR101995753B1 (ko) 2019-07-03
BR112013027420A2 (pt) 2016-08-09
WO2012148873A2 (en) 2012-11-01
RS54831B1 (sr) 2016-10-31
CY1117606T1 (el) 2017-04-26
MX2013012500A (es) 2014-02-03
JP2016178948A (ja) 2016-10-13
PL2701499T5 (pl) 2021-12-13
HK1220866A1 (en) 2017-05-19
AU2018236913A1 (en) 2018-10-25
KR20140024909A (ko) 2014-03-03
SI2701499T1 (sl) 2016-10-28
JP2014516518A (ja) 2014-07-17
LT2989893T (lt) 2019-09-10
SI2989893T1 (sl) 2019-10-30
ES2573828T5 (es) 2022-02-28
RU2013152221A (ru) 2015-05-27
DK2701499T4 (da) 2021-11-15
RS54831B2 (sr) 2021-12-31
IL228929A0 (en) 2013-12-31
HK1193718A1 (zh) 2014-10-03
AU2016202609B2 (en) 2018-07-12
HUE045401T2 (hu) 2019-12-30
CN103596424A (zh) 2014-02-19
RS59331B1 (sr) 2019-10-31
AU2016202609A2 (en) 2017-02-02
WO2012148873A4 (en) 2013-03-14
AU2012249953B2 (en) 2016-01-28
HRP20191680T1 (hr) 2019-12-13
DK2701499T3 (en) 2016-05-23
HUE027949T2 (en) 2016-11-28
EP2989893A1 (en) 2016-03-02
EP2701499A2 (en) 2014-03-05
CA2846806A1 (en) 2012-11-01
SG194466A1 (en) 2013-12-30
EP2989893B1 (en) 2019-06-19
CN105884887A (zh) 2016-08-24
SMT201600133B (it) 2016-07-01
HRP20160484T1 (hr) 2016-06-03
US20150313193A1 (en) 2015-11-05
NZ617158A (en) 2016-04-29
CN103596424B (zh) 2016-01-20
HRP20160484T4 (hr) 2021-12-10
EP2701499B8 (en) 2016-03-16
RU2614859C2 (ru) 2017-03-29
JP6393613B2 (ja) 2018-09-19
EP2701499B1 (en) 2016-02-10
AU2012249953A1 (en) 2013-05-02
JP6522557B2 (ja) 2019-05-29
PL2989893T3 (pl) 2019-12-31

Similar Documents

Publication Publication Date Title
RU2017108634A (ru) Отличные от человека животные, экспрессирующие антитела с общей легкой цепью
JP2014516518A5 (OSRAM)
RU2013102595A (ru) Мыши, экспрессирующие гибридную легкую цепь иммуноглобулина
RU2015135884A (ru) Не являющиеся человеком животные с модифицированными последовательностями тяжелых цепей иммуноглобулинов
JP2018138047A5 (OSRAM)
ES2712207T3 (es) Ratones que expresan un repertorio limitado de cadenas ligeras de inmunoglobulina
IL268675A (en) Humanized rodents that express heavy chains that include VL complexes
CN104244709B (zh) 共同轻链小鼠
WO2013061098A3 (en) Functional isotype switching of chimaeric antibody chains & chimaeric animals expressing different igh isotypes
JP2015505477A5 (OSRAM)
RU2013109068A (ru) Мыши, у которых вырабатываются связывающие белки, содержащие vl-домены
JP2013535213A5 (OSRAM)
HRP20151188T4 (hr) Miš sa zajedničkim lakim lancem
JP2021505141A5 (OSRAM)
RU2016139418A (ru) Мыши с ограниченной тяжелой цепью иммуноглобулина
JP2014110814A5 (OSRAM)
RU2021129958A (ru) Отличные от человека животные со сконструированным локусом легкой лямбда-цепи иммуноглобулина
EP3741862A1 (en) Animals, repertoires & methods for the production of human antibodies
RU2016141307A (ru) Отличные от человека животные, которые вырабатывают однодоменные связывающие белки
HRP20191233T1 (hr) Antitijela lakog lanca modificirana histidinom i genetski modificirane nehumane životinje za dobivanje istih
US11707056B2 (en) Animals, repertoires and methods
HK1250038A1 (zh) 选择结合抗原的轻链可变区的非人动物
RU2018130010A (ru) Животные, отличные от человека, имеющие мутантный ген кинурениназы
RU2022109215A (ru) Гуманизированные грызуны, которые экспрессируют тяжелые цепи, содержащие домены vl
RU2015124041A (ru) Оптимизированная экспрессионная кассета для экспрессии полипептида с высоким выходом

Legal Events

Date Code Title Description
FA93 Acknowledgement of application withdrawn (no request for examination)

Effective date: 20200316